Non-invasive Heart Failure Monitoring Using Novel Acceleration Sensors System
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to explore the feasibility of monitoring hemodynamic changes, which result from heart failure exacerbations, by recording the respiratory effort, chest wall dynamics and quantifying the development of dyspnea by using miniature mechanical sensors that are attaches to the chest.
| Condition | Intervention |
|---|---|
|
Heart Failure |
Device: "Pneumedicare"s monitoring system. Device: "Pneumedicare"s monitoring system |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Non-invasive Heart Failure Monitoring Using Novel Acceleration Sensors System |
- earliest non-invasive signs for lung congestion and deterioration in the heart failure [ Time Frame: 18 months ] [ Designated as safety issue: No ]Exploring the feasibility of monitoring hemodynamic changes, which result from heart failure exacerbations, by recording the respiratory effort, chest wall dynamics and quantifying the development of dyspnea by using miniature mechanical sensors that are attaches to the chest.
| Estimated Enrollment: | 50 |
| Study Start Date: | June 2011 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: "Pneumedicare"s monitoring system
Single arm study - "Pneumedicare"s monitoring system is used for monitoring heart failure patients
|
Device: "Pneumedicare"s monitoring system.
50 patients hospitalized due to the decompensated HF are considered for entry. 3 patches will be attached to the patients' thorax that include motion sensors. The system will be attached to the patients at the start of treatment. Patient's signals will be recorded during the entire treatment in the hospital, to the point that there is an improvement in their health condition.
Other Name: "Pneumedicare"s monitoring system for heart failure patients
Device: "Pneumedicare"s monitoring system
Non invasive clinical follow-up of patients with HF deterioration and improvement, by a device-based algorithm. The system comprises of patches attached to the patients' thorax that include motion sensors (Accelerometers) that measure the chest wall dynamics and the mechanics of lung inflation and deflation.
Other Name: "Pneumedicare"s monitoring system for heart failure patients
|
Detailed Description:
Pulmonary veins congestion and fine changes in alveolar transudative effusion accumulation affect lung mechanics (compliance) and the respiratory effort. Moreover, the associated state of oxygen de-saturation is compensated by an increase in the respiratory effort. These changes in the respiratory effort are reflected in chest wall dynamics and may provide the earliest non-invasive sign for lung congestion and deterioration in the heart failure.
The research system comprises of patches attached to the patients' thorax that include motion sensors (Accelerometers) that measure the chest wall dynamics and the mechanics of lung inflation and deflation. The signals are acquired by a miniaturized device that amplifies and samples the signals, stores and analyzes the data and displays the trends on the screen.
Eligibility| Ages Eligible for Study: | 20 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Acute decompensated HF
- Decompensated chronic HF in patients with NYHA class III-IV symptoms
- Age over 20 years
- Ejection fraction reduced below 35% OR doppler evidence of impaired left ventricular diastolic filling
Exclusion Criteria:
- Inability or unwillingness to follow the study protocol
Contacts and Locations| Contact: Shmuel rispler, MD PhD | 972-4-8542180 | s_rispler@rambam.health.gov.il |
| Contact: Amir Landesberg, MD PhD | 972-505482249 | Amir@bm.technion.ac.il |
| Israel | |
| Rambam Health Care Campus | Not yet recruiting |
| Haifa, Israel, 31096 | |
| Contact: Shmuel Rispler, MD PhD 972-4-8542180 s_rispler@rambam.health.gov.il | |
| Contact: Amir Landesberg, MD PhD 972-505482249 Amir@bm.technion.ac.il | |
| Principal Investigator: Shmuel Rispler, MD PhD | |
| Principal Investigator: | Shmuel Rispler, MD PhD | Rambam Medical Center Haifa Israel |
More Information
No publications provided
| Responsible Party: | Shmuel Rispler, Rambam Health Care Campus, P.O.B. 9602, Haifa 31096, Israel |
| ClinicalTrials.gov Identifier: | NCT01377350 History of Changes |
| Other Study ID Numbers: | 0550-10ctil, ministry of health Israel |
| Study First Received: | May 18, 2011 |
| Last Updated: | June 20, 2011 |
| Health Authority: | Israel: Ministry of Health |
Keywords provided by Rambam Health Care Campus:
|
Heart failure monitoring |
Additional relevant MeSH terms:
|
Heart Failure Heart Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on May 22, 2013